TORONTO, Feb. 17, 2021 (GLOBE NEWSWIRE) — Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that, further to its press release dated December 21, 2020, it has entered into an asset purchase agreement (the “Agreement”) with…

Source

Previous articleVideo Roundtable: The Future of Ketamine Therapy
Next articleJohn C. Lilly: Father of LSD In the Sensory Deprivation Tank